Skip to Main Content

Paper Details

Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation.
Mol Cancer Ther
2
2022
Tumor, Tumors, breast cancer, cancer, patients, resistant populations, resistant subclone, tumor, tumors
Author NameAffiliation
Walid K ChatilaMemorial Sloan Kettering Cancer Center
Howard I ScherMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
  • 1 - 6

Datasets

Release 1.2